Adderall (dextroamphetamine-amphetamine) is a combination of two synthetic agents with central nervous system stimulant activity. Both agents are non-catecholamine, sympathomimetic agents that elevate blood pressure and cause bronchodilation. These agents are commonly abused psychostimulant drugs that induce psychologic dependence manifested by elevated mood, increased wakefulness, concentration, physical performance and a feeling of well-being. Tolerance to various effects develops unequally, so that tachycardia and enhanced alertness diminish while psychotoxic effects (hallucinations and delusions) may occur.
Researchers at the University of Copenhagen have gained new insight into the mechanism behind a protein dopamine transporter that could help in the development of future medical treatment against cocaine addiction.
A national survey of students in U.S. middle schools and high schools shows some important improvements in levels of substance use.
A darting mouse may hold an important clue in the development of Attention Deficit Hyperactivity Disorder (ADHD), autism and bipolar disorder, according to a study by a Vanderbilt University-led research team recently published in the Proceedings of the National Academy of Sciences.
Shire plc today announced that it has received further guidance from the U.S. Food and Drug Administration on the regulatory path for SHP 465 (triple-bead mixed amphetamine salts MAS), an investigational oral stimulant medication being evaluated as a potential treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) in adults.
Shire plc, the global specialty biopharmaceutical company, and ArmaGen, a US privately held biotechnology company, today announced a worldwide licensing and collaboration agreement for AGT-182, an investigational enzyme replacement therapy (ERT) for the potential treatment of both the central nervous system (CNS) and somatic manifestations in patients with Hunter syndrome (MPS II).
In a bizarre attempt to have it both ways, the Supreme Court held that a small evangelical Protestant college in Illinois did not have to include contraceptive coverage in employee health insurance even though it didn't fill out the paperwork the government required for claiming an exemption. ..
"It does not surprise me that some children are being given medicine as the easy way out but that doesn't mean it's the right way to do it," says Max Wiznitzer, MD, a pediatric neurologist at University Hospitals Rainbow Babies & Children's Hospitals about the Center for Disease Control's estimate 10,000 toddlers receive medication for attention-deficit/hyperactivity disorder (ADHD).
Following a May 15, 2014, meeting with the U.S. Food and Drug Administration (FDA), Shire plc, the global specialty biopharmaceutical company, announces today that it intends to submit a New Drug Application for lifitegrast as a treatment for the signs and symptoms of dry eye disease in adults in the first-quarter 2015, as we complete remaining chemistry and manufacturing work.
Researchers at the University of California, San Diego School of Medicine have discovered impaired neuronal activity in the parts of the brain associated with anticipatory functioning among occasional 18- to 24-year-old users of stimulant drugs, such as cocaine, amphetamines and prescription drugs such as Adderall.
Under the Affordable Care Act (ACA), changes in income and family circumstances are likely to produce frequent transitions in eligibility for Medicaid and health insurance Marketplace coverage for low- and middle-income adults.
By the beginning of the month, 4.2 million people had selected a plan. But that doesn't mean they have insurance. Reporters on a conference call asked about the number who had paid, and the administration's representatives said they don't know.
Shire plc (LSE: SHP, NASDAQ: SHPG) today announced its support of Rare Disease Day and invites others to join them in its continued commitment to the rare disease community.
Impax Laboratories, Inc. today reported fourth quarter and full year ended December 31, 2013 results.
Shire plc, announces that its subsidiary Shire US Inc. has entered into an agreement to supply an authorized generic version of its product Adderall XR.
A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs.
Today's headlines including stories detailing how certain health law provisions are factoring in to the continuing congressional budget stalemate.
Shire LLC has settled its litigation against Teva Pharmaceuticals USA Inc. ("Teva") in connection with Teva's Abbreviated New Drug Application ("ANDA") for a generic version of Shire's INTUNIV (guanfacince) Extended Release Tablets for the treatment of Attention Deficit Hyperactivity Disorder.
As high schoolers prepare for final exams, teens nationwide may be tempted to use a "study drug" -- a prescription stimulant or amphetamine -- to gain an academic edge. But a new University of Michigan poll shows only one in 100 parents of teens 13-17 years old believes that their teen has used a study drug.
Shire plc, the global specialty biopharmaceutical company, announces that it will present scientific data in 7 poster presentations at the American Psychiatric Association 166th Annual Meeting in San Francisco, May 18-22.
Five states have moved to adopt tighter abortion regulations, including North Dakota, where a new law prohibits abortions as soon as a fetal heartbeat is detected. Jeffrey Brown gets perspectives from Charmaine Yoest of Americans United for Life and Ilyse Hogue of NARAL Pro-Choice America (4/30).